Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of pravastatin is not dependent on CYP3A. Note, the European product label for Paxlovid, but not the British product label for Paxlovid, advises to consider temporary discontinuation of pravastatin during treatment with Paxlovid.